Androgen Deprivation Therapy Differentially Impacts Bone and Muscle in the Short Term in Physically Active Men With Prostate Cancer.
ANDROGEN DEPRIVATION
BONE
MALE OSTEOPOROSIS
MUSCLE
PROSTATE CANCER
Journal
JBMR plus
ISSN: 2473-4039
Titre abrégé: JBMR Plus
Pays: England
ID NLM: 101707013
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
23
04
2021
revised:
20
09
2021
accepted:
08
10
2021
entrez:
26
1
2022
pubmed:
27
1
2022
medline:
27
1
2022
Statut:
epublish
Résumé
Androgen deprivation therapy (ADT) is a cornerstone of advanced prostate cancer (PCa) therapy. Its use is associated with a loss of bone mineral density (BMD) and a greater risk of falls and osteoporotic fractures. In this prospective cohort study, we examined the impact of ADT on muscle and bone strength in men initiating ADT for PCa. Participants were evaluated at three time points: immediately before (week 0), and 6 and 24 weeks after ADT initiation. Study measures included fasting blood levels (for markers of muscle and bone metabolic activity), MRI and QCT imaging (for muscle fat content, and bone density and architecture), and validated clinical tests of muscle strength and gait. Sixteen men completed all study visits. At baseline and throughout the study, participants exercised a median of four times/week, but still experienced weight gain (+2.0 kg at week 24 versus week 0,
Identifiants
pubmed: 35079681
doi: 10.1002/jbm4.10573
pii: JBM410573
pmc: PMC8770993
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e10573Subventions
Organisme : NIBIB NIH HHS
ID : T32 EB028093
Pays : United States
Informations de copyright
© 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.
Références
BJU Int. 2013 May;111(5):745-52
pubmed: 23331464
J Gerontol A Biol Sci Med Sci. 1995 Jan;50A(1):M28-34
pubmed: 7814786
N Engl J Med. 2013 Dec 19;369(25):2457
pubmed: 24350954
Nat Rev Urol. 2016 Jun;13(6):353-64
pubmed: 27112391
N Engl J Med. 2005 Jan 13;352(2):154-64
pubmed: 15647578
Bone. 2019 Oct;127:367-375
pubmed: 31189088
J Bone Miner Res. 2005 Oct;20(10):1785-91
pubmed: 16160736
J Clin Oncol. 2012 Sep 10;30(26):3271-6
pubmed: 22649143
N Engl J Med. 2009 Aug 20;361(8):745-55
pubmed: 19671656
J Urol. 2003 Jun;169(6):2008-12
pubmed: 12771706
J Frailty Aging. 2020;9(1):57-63
pubmed: 32150215
Lancet Diabetes Endocrinol. 2018 Nov;6(11):901-910
pubmed: 29572126
J Clin Invest. 2016 Mar 1;126(3):1114-25
pubmed: 26901812
Eur J Endocrinol. 2020 Aug;183(2):181-189
pubmed: 32454455
BJU Int. 2019 Feb;123(2):261-269
pubmed: 30239116
Med Sci Sports Exerc. 2018 Mar;50(3):393-399
pubmed: 29036016
Osteoporos Int. 2018 Feb;29(2):287-303
pubmed: 28971226
Qual Life Res. 2018 Jul;27(7):1885-1891
pubmed: 29569016
Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86
pubmed: 12072048
J Clin Endocrinol Metab. 2005 Dec;90(12):6410-7
pubmed: 16189261
Phys Ther. 2003 Dec;83(12):1072-9
pubmed: 14640866
J Bone Miner Res. 2013 Sep;28(9):1857-65
pubmed: 23671010
J Am Geriatr Soc. 2017 Jul;65(7):1414-1419
pubmed: 28263373
Osteoporos Int. 2019 Jan;30(1):115-125
pubmed: 30324413
Endocrine. 2014 Mar;45(2):271-8
pubmed: 23649460
Scand J Urol. 2019 Feb;53(1):34-39
pubmed: 30777478
Med Sci Sports Exerc. 2009 Jul;41(7):1510-30
pubmed: 19516148
J Med Imaging Radiat Oncol. 2014 Apr;58(2):223-8
pubmed: 24118850
J Clin Invest. 2000 Dec;106(12):1553-60
pubmed: 11120762
Arch Gerontol Geriatr. 2004 Jan-Feb;38(1):11-26
pubmed: 14599700
JAMA Intern Med. 2017 Apr 1;177(4):471-479
pubmed: 28241231
Osteoporos Int. 2008 Oct;19(10):1465-71
pubmed: 18338096
Sci Rep. 2016 Aug 16;6:31553
pubmed: 27527335
Bone. 2019 Nov;128:115053
pubmed: 31473261
J Heart Valve Dis. 2013 May;22(3):317-25
pubmed: 24151757
Osteoporos Int. 2014 Feb;25(2):645-51
pubmed: 23903956
Bone. 2015 Nov;80:67-78
pubmed: 26453497